Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alcoa Inc (AA), F5 Networks, Inc. (FFIV) & More: Three Stocks to Get on Your Watchlist

Page 1 of 2

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I’d be unable to keep up on my favorite sectors and see what’s really moving the market. Even worse, I’d be lost when the time came to choose which stock I’m buying or shorting next.

Alcoa Inc (NYSE:AA)

Today is Watchlist Wednesday, so I’m discussing three companies that have crossed my radar in the past week — and at what point I may consider taking action on these calls with my own money. Keep in mind that these aren’t concrete buy or sell recommendations, nor do I guarantee I’ll take action on the companies being discussed. What I can promise is that you can follow my real-life transactions through my profile and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.

ArcelorMittal (ADR) (NYSE:MT)
If you haven’t been following the steel industry much, simply pulling a list of the most recent 52-week lows will get you up-to-date in no time. ArcelorMittal (ADR) (NYSE:MT), a steel producer and iron ore and coal miner, has all the makings of a company investors would thoroughly dislike right now. It has net debt of $21.9 billion, is dealing with weak steel prices and demand throughout Europe, its largest market, and is struggling under the weight of weak iron ore and coal prices. And yet, I think ArcelorMittal could be ripe for the bottom-fisher willing to take on a little risk.

My reasoning for this is twofold. First, I turn to Alcoa Inc (NYSE:AA)‘s results last night for an indication of the health of the metals market. While the results aren’t anything to write home about, the bottom-line profit was better than expected, and more important, Alcoa Inc (NYSE:AA) stuck by its original forecast calling for 7% aluminum growth worldwide, with strength coming from a multitude of sectors. That bodes well for ArcelorMittal (ADR) (NYSE:MT), which is a major steel supplier to the automotive and construction industry.

Second, I’m not certain that we aren’t overreacting as investors to the austerity measures we’re seeing in Europe. Yes, the automotive industry has been weak, but ArcelorMittal is likely to see big gains in Latin American markets, where construction is still relatively strong. Brazil, for instance, recently recorded a record 3.8 million auto sales, which demonstrates the growth ArcelorMittal could deliver by looking even more rigorously to overseas markets.

I even admit that ArcelorMittal’s net debt makes me think twice about owning the stock, but with its share price at eight times forward earnings, I think the worst-case scenario in Europe is already baked in.

Allergan, Inc. (NYSE:AGN)
I’m sorry, longtime Allergan, Inc. (NYSE:AGN) fans, but it’s not Allergan’s extensive pipeline that’s drawn my attention to the stock, it’s the expected decision by the Food and Drug Administration on inhaled migraine medication Levadex by or before this coming Monday.

Levadex, if you recall, was developed by MAP Pharmaceuticals and licensed out to Allergan, Inc. (NYSE:AGN). The inhaled medication received a complete response letter in late March 2012 not because of the safety or efficacy surrounding the drug — clinical trials demonstrated more than enough efficacy to merit an approval. Instead, MAP’s manufacturing and delivery of the drug is what came under scrutiny. With the company having spent a year now refining its manufacturing and delivery process with the FDA, the assumption would be that MAP has all of its ducks in a row now.

Page 1 of 2
Loading Comments...